智通财经APP获悉，港股今早探底回升，午后涨幅有所扩大，恒生指数成功站上两万五大关。截止收 盘，恒生指数涨0.69%或171点，报25081.63点，全日成交额为2457.48亿港元；恒生国企指数涨0.55%， 报8981.73点；恒生科技指数涨0.26%，报5546.73点。 国泰海通证券指出，年初以来的中国资产重估行情中，港股整体涨幅较A股更为可观，创新药、新消 费、AI应用等方向亮点纷呈。借鉴历史上港股占优行情，该行认为本轮行情或和其中的2012-2014年具 有一定相似性，港股表现强劲源于部分资产更具稀缺性。展望未来，港股稀缺性资产基本面更优，或吸 引南下持续流入，支撑港股继续向上。 蓝筹股表现 至6%，这带来显著的正向经营杠杆、竞争减少和盈利预估的提升。尽管近期表现优异，但如果增长得 以维持，该行认为该行业估值仍偏低。 1. 苹果概念表现亮眼。截至收盘，高伟电子(01415)涨9.62%，报29.86港元；鸿腾精密(06088)涨6.91%， 报3.25港元；舜宇光学(02382)涨3.3%，报76.75港元；蓝思科技(06613)涨2.93%，报21.1港元。 美国当地时间8月6日，苹果公司宣布追 ...

Core Viewpoint - The stock performance of CSPC Pharmaceutical Group has been weak due to market panic over the National Healthcare Security Administration's announcement of the 11th round of volume-based procurement (VBP) measures, particularly the requirement for each medical institution to maintain an annual demand of no less than 80% of the average usage for the 2023-2024 fiscal year [1] Group 1 - The report notes that the volume-based procurement requirements remain unchanged compared to previous years, and with the introduction of optimization measures for the VBP policy, the market expects these requirements to become more lenient [1] - CSPC Pharmaceutical Group was not included in any products in the 11th round of VBP, indicating that the company's fundamentals are sound and its business development is in line with expectations [1]

Core Viewpoint - The stock price of CSPC Pharmaceutical Group Limited (01093) experienced a decline of 2.88% on August 7, trading at HKD 9.77 per share with a transaction volume of HKD 302 million [1]. Group 1: Company Overview - CSPC Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company primarily engaged in the production of finished drugs and active pharmaceutical ingredients, with a core development strategy focused on innovative drugs [1]. - The company has a strong product portfolio in the treatment areas of neurological diseases, oncology, anti-infection, and cardiovascular diseases [1]. - CSPC boasts an international R&D team dedicated to the discovery, research, and development of small molecule targeted drugs, nanomedicines, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and biopharmaceuticals in the immunology field [1]. Group 2: Financial Performance - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 7.015 billion and a net profit of HKD 1.478 billion [2].

Core Insights - Adidas reported a 7% year-on-year revenue growth for FY2025H1, reaching €12.105 billion, with a net profit increase of 121% to €798 million [4] - The brand's revenue growth was 14% on a currency-neutral basis, with all regional markets achieving double-digit growth [4] - The company maintains its full-year guidance, expecting high single-digit revenue growth on a currency-neutral basis for FY2025, with double-digit growth for the Adidas brand [4] Market Trends - The domestic market indices showed positive performance, with the Shanghai Composite Index closing at 3,617.60, up 0.96% [3] - The textile and apparel sector experienced a decline of 2.14% this week, underperforming the broader market [5] - Retail sales of sports and entertainment products grew significantly, with a 22.2% year-on-year increase in the first half of 2025 [5] Industry Dynamics - The Chinese gold consumption in the first half of 2025 was 505.205 tons, a decrease of 3.54% year-on-year, with jewelry consumption dropping by 26% [5] - The pharmaceutical industry is seeing advancements in innovative drugs, particularly in obesity treatments with GLP-1 and Amylin therapies showing promising results in clinical trials [8][11] - In the biopharmaceutical sector, ADC drugs for lung cancer are demonstrating significant efficacy, with several products showing improved outcomes in clinical trials [10][12]

Major Events - Shiyao Group's (01093) application for the listing of Semaglutide injection has been accepted by the National Medical Products Administration (NMPA) [1] - Gilead Sciences-B (01672) has completed the enrollment of overweight or obese subjects in the Phase IIa study of the small molecule oral GLP-1R agonist ASC30 in the United States [1] - China Biopharmaceutical (01177) has received NMPA approval for the clinical trial application of TQC3302 "ICS/LAMA/LABA soft mist inhalation preparation" [1] - Jiaogepeng Holdings (01450) plans to acquire 100% equity of Hangzhou Jiaogepeng Education Technology Co., Ltd. for 180 million yuan [1] Financial Data - China Tower (00788) reported a mid-term profit attributable to shareholders of 5.757 billion yuan, an increase of 8.0% year-on-year, with the revenue share from its two wings business exceeding 14% [1] - Techtronic Industries (00669) reported a mid-term profit attributable to shareholders of 628 million USD, an increase of 14.17% year-on-year, with a dividend of 1.25 HKD per share [1] - Yum China (09987) reported a second-quarter operating profit of 304 million USD, a year-on-year increase of 14% [1] - Zibuyu (02420) issued a profit warning, expecting mid-term revenue to increase by approximately 30%-40% to between 1.9 billion and 2.047 billion yuan [1] - Angelalign (06699) issued a profit warning, expecting net profit for the first half of the year to be approximately 13.4 million to 14.8 million USD, a year-on-year increase of approximately 538.1% to 604.8% [1] - Boya Interactive (00434) issued a profit warning, expecting mid-term profit attributable to shareholders to decrease by approximately 25% to 35% [1] - Zhenjiu Lidu (06979) issued a profit warning, expecting mid-term net profit attributable to shareholders to decline by 23% to 24% [1] - Fourth Paradigm (06682) expects a narrowed adjusted net loss for the mid-term, down 68% to 73% year-on-year [1]

智通财经APP讯，石药集团(01093)发布公告，公司附属公司石药集团百克(山东)生物制药股份有限公司 开发的司美格鲁肽注射液(该产品)的上市申请已获中国国家药品监督管理局受理。本次申报的适应症为 成人2型糖尿病患者的血糖控制。 基于在疗效、安全性、制剂等方面的优势，该产品具有显著的临床应用价值。集团也在积极推进该产品 针对肥胖╱超重适应症的Ⅲ期临床试验，以期使更多患者从中获益。 该产品是基于天然人胰高血糖素样肽-1(GLP-1)结构的胰高血糖素样肽-1受体激动剂，为化学合成法制 备的司美格鲁肽制剂，按照化药注册分类2.2类新药申报，属含有已知活性成份的新处方工艺且具有明 显临床优势的药品。GLP-1是由肠道L细胞分泌的肠源性激素，可通过与广泛分布于全身多种器官和组 织的GLP-1受体结合而发挥作用，并通过多重机制实现降糖、减重以及心血管和肾脏保护等方面的综合 获益。 本次申请基于一项关键性Ⅲ期临床试验。该临床试验结果表明，在经二甲双胍治疗血糖控制不佳的2型 糖尿病患者中，与诺和诺德开发的司美格鲁肽相比，该产品展现出高度一致的疗效，且其胃肠道反应发 生率略低。该产品遵循相关指导原则，通过药学、非临床、临床药代 ...

每经AI快讯，8月5日，石药集团公告，附属公司石药集团百克(山东)生物制药股份有限公司开发的司美 格鲁肽注射液的上市申请已获国家药品监督管理局受理。本次申报的适应症为成人2型糖尿病患者的血 糖控制。 ...

Core Viewpoint - The company has received acceptance for the listing application of its semaglutide injection, aimed at controlling blood sugar levels in adults with type 2 diabetes, from the National Medical Products Administration of China [1] Group 1: Product Development - The semaglutide injection is a GLP-1 receptor agonist developed based on the natural structure of human glucagon-like peptide-1, classified as a new drug under category 2.2, which contains known active ingredients and demonstrates significant clinical advantages [1] - The application is based on a pivotal phase III clinical trial, which showed that the product exhibited highly consistent efficacy compared to Novo Nordisk's semaglutide in patients with poorly controlled blood sugar after metformin treatment, with slightly lower gastrointestinal reaction rates [1] Group 2: Clinical Value and Future Prospects - The product has significant clinical application value due to its advantages in efficacy, safety, and formulation [2] - The company is actively advancing phase III clinical trials for the product targeting obesity/overweight indications, aiming to benefit more patients [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 獲國家藥品監督管理局受理 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本公司附屬公司石藥集團百克（ 山東 ）生物製藥股份有限公司開發的司美格魯肽注射液 （「該產品」）的上市申請已獲中華人民共和國國家藥品監督管理局受理。本次申報的適應症 為成人2型糖尿病患者的血糖控制。 該產品是基於天然人胰高血糖素樣肽-1（「GLP -1」）結構的胰高血糖素樣肽-1受體激動劑， 為化學合成法製備的司美格魯肽製劑，按照化藥註冊分類2.2類新藥申報，屬含有已知活性 成份的新處方工藝且具有明顯臨床優勢的藥品。GLP -1是由腸道L細胞分泌的腸源性激素， 可通過與廣泛分布於全身多 種器官和組織的GLP -1受體結合而發揮 作用，並通過多重機制 實現降糖、減重以及心血管和腎臟保護等方面的綜合獲益。 本次申請基於一項關鍵性Ⅲ ...

金融界8月5日消息，上证指数高开高走，中证港股通生物科技主题指数 (港股通生物科技，932253)报 1886.25点。 数据统计显示，中证港股通生物科技主题指数近一个月上涨22.20%，近三个月上涨54.39%，年至今上 涨108.66%。 据了解，中证港股通生物科技主题指数从港股通范围内选取50只业务涉及生物药品、制药与生物科技服 务等领域的上市公司证券作为指数样本，以反映港股通范围内生物科技主题上市公司证券的整体表现。 该指数以2018年12月28日为基日，以1000.0点为基点。 从指数持仓来看，中证港股通生物科技主题指数十大权重分别为：百济神州（13.23%）、信达生物 （12.79%）、药明生物（9.82%）、康方生物（8.87%）、中国生物制药（6.39%）、石药集团 （6.11%）、三生制药（4.69%）、翰森制药（3.27%）、药明康德（3.03%）、科伦博泰生物-B （2.67%）。 本文源自：金融界 作者：行情君 从中证港股通生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通生物科技主题指数持仓样本的行业来看，化学药占比40.03%、生物药品占比38.7 ...